# Cidara Therapeutics Inc.

Canonical: https://abierto.us/vendors/cidara-therapeutics-inc-fkp3jz9runy9

- UEI: FKP3JZ9RUNY9
- CAGE: 7A5L2
- Location: San Diego, CA
- Awards in window: 1 (2 transactions), $58,051,983 obligated, September 30, 2025 to June 2, 2026

## Awarding agencies

- Office of Assistant Secretary for Preparedness and Response: 1 awards, $58,051,983

## Industries

- 541714 Research and Development in Biotechnology (except Nanobiotechnology): $58,051,983

## Competition

- Full and Open Competition: 1 awards

## Solicitations won

- Development of CD388 as a long-lasting prophylactic anti-viral option for protection against the health impacts caused by influenza (75A50125C00017), $339,189,481. https://abierto.us/opportunities/75a50125c00017

## Largest awards

- 75A50125C00017 (definitive contract): $58,051,983, Barda - Aspr / Daappo / Barda DCMA. Development of CD388 as a Long-Lasting Prophylactic Anti-Viral Option for Protection Against the Health Impacts Caused by Influenza. https://www.usaspending.gov/award/CONT_AWD_75A50125C00017_7505_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/cidara-therapeutics-inc-fkp3jz9runy9.